Low-Dose N-Butyldeoxynojirimycin (OGT 918) for Type I Gaucher Disease

By Heitner R.   Elstein D.   Aerts J.   Weely S.   Zimran A.  

Blood Cells, Molecules, and Diseases, Vol. 28, Iss. 2, 2002-02 ,pp. : 127-133

Academic Press

Access to resources Recommend Favorite

Comparative Efficacy of Dose Regimens in Enzyme Replacement Therapy of Type I Gaucher Disease

By Altarescu G.   Schiffmann R.   Parker C.C.   Moore D.F.   Kreps C.   Brady R.O.   Barton N.W.  

Blood Cells, Molecules, and Diseases, Vol. 26, Iss. 4, 2000-08 ,pp. : 285-290

Academic Press

Access to resources Recommend Favorite

Type 2 Gaucher Disease: An Expanding Phenotype

By Tayebi N.   Stone D.L.   Sidransky E.  

Molecular Genetics and Metabolism, Vol. 68, Iss. 2, 1999-10 ,pp. : 209-219

Academic Press

Access to resources Recommend Favorite

Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature

By Fost M.  

Annals of Hematology, Vol. 87, Iss. 6, 2008-06 ,pp. : 439-449

Springer Publishing Company

Access to resources Recommend Favorite

Successful pregnancy outcome in a patient with Gaucher's disease and antiphospholipid syndrome

By Sherer Y.   Dulitzki M.   Levy Y.   Livneh A.   Shoenfeld Y.   Langevitz P.  

Annals of Hematology, Vol. 81, Iss. 3, 2002-03 ,pp. : 161-163

Springer Publishing Company

Access to resources Recommend Favorite